What Will Happen to Trillium Therapeutics Inc Next? The Stock Just Upped A Lot

 What Will Happen to Trillium Therapeutics Inc Next? The Stock Just Upped A Lot

The stock of Trillium Therapeutics Inc (TSE:TR) is a huge mover today! About 22,931 shares traded hands or 248.76% up from the average. Trillium Therapeutics Inc (TSE:TR) has risen 53.17% since March 29, 2016 and is uptrending. It has outperformed by 50.65% the S&P500.
The move comes after 7 months positive chart setup for the $147.01 million company. It was reported on Nov, 2 by Barchart.com. We have $55.76 PT which if reached, will make TSE:TR worth $283.73M more.

More notable recent Trillium Therapeutics Inc (TSE:TR) news were published by: Marketwatch.com which released: “Trillium Therapeutics Inc.” on August 24, 2009, also Medgadget.com with their article: “Trillium Therapeutics Inc Clinical Trial Review, Market Size, Segment, and …” published on November 01, 2016, Etfdailynews.com published: “Trillium Therapeutics Inc. (TRIL): Finding The Next Blockbuster Biotech Stock” on June 23, 2015. More interesting news about Trillium Therapeutics Inc (TSE:TR) were released by: Quotes.Wsj.com and their article: “News Trillium Therapeutics Inc.TRIL” published on December 20, 2014 as well as Seekingalpha.com‘s news article titled: “Trillium Therapeutics Is An Overvalued Biotech Stock” with publication date: April 14, 2015.

Trillium Therapeutics Inc is a Canada clinical stage immuno-oncology firm developing therapies for the treatment of cancer. The company has a market cap of $147.01 million. The Company’s SIRPaFc program, which is under Phase I clinical trial, is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the fragment crystallizable (Fc) region of a human immunoglobulin (IgG1). It currently has negative earnings. It acts as a soluble decoy receptor, preventing CD47 from delivering its inhibitory signal.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment